PDCD1 and melanoma: In melanoma, comparing PD-L1+ vs. PD-L1(−) tumors, we found an overexpression of genes involved in CD8+ T-cell activation (e.g., CD8A, IFNG) and other immunosuppressive pathways (e.g., LAG3 and IL10) in PD-L1+ tumors, suggesting the coordinate expression of multiple immunological factors that could influence response to anti-PD-1 therapy.